


Skin Cancer Recruitment Overview

National Recruitment
National Commercial & Non Commercial Activity
National ABF Category
Trust Overview
Trust Type Comparisons
Open Studies
EOIs

May 2017

Skin Cancer - National Recruitment



Skin Cancer - National Commercial & Non Commercial Activity



National Institute for
Health Research

LCRNName	FY1415				FY1516				FY1617			
	Commercial	Non-Commercial	Total	Adj. for Pop Rank	Commercial	Non-Commercial	Total	Adj. for Pop Rank	Commercial	Non-Commercial	Total	Adj. for Pop Rank
East Midlands	8	12	20	13	7		7	13	6		6	12
Eastern	60	27	87	2	25	58	83	4	15	35	50	3
Greater Manchester	10	6	16	10	20	48	68	3	23	5	28	4
Kent, Surrey and Sussex	3	4	7	14	3		3	15				14 - 15
North East and North Cumbria	11	4	15	12	12	1	13	9	4		4	13
North Thames	14	17	31	9	3	33	36	8	2	30	32	7
North West Coast	63	13	76	3	14	15	29	7	10	19	29	5
North West London	1		1	15		2	2	14		6	6	10
South London	43	2	45	5	56	18	74	2	28	56	84	1
South West Peninsula	19	4	23	8	5	1	6	10	5	3	8	9
Thames Valley and South Midlands	30	14	44	4	21	27	48	5	8	9	17	6
Wessex	7	29	36	6	5	2	7	11	7	4	11	8
West Midlands	14	15	29	11	8	6	14	12		8	8	11
West of England	27	2	29	7	24	19	43	6				14 - 15
Yorkshire and Humber	34	219	253	1	13	155	168	1	17	90	107	2


Skin Cancer - National ABF Category



National Institute for
Health Research

Network	2014-15					2015-16					2016-17				
	Commercial	Interventional	Observational	Total	Adj. for pop rank	Commercial	Interventional	Observational	Total	Adj. for pop rank	Commercial	Interventional	Observational	Total	Adj. for pop rank
East Midlands	8	4	8	20	13	7			7	13	6			6	12
Eastern	60	27		87	2	25	58		83	4	15	33	2	50	3
Greater Manchester	10	3	3	16	10	20	45	3	68	3	23	5		28	4
Kent, Surrey and Sussex	3		4	7	14	3			3	15					14 - 15
North East and North Cumbria	11	4		15	12	12	1		13	9	4			4	13
North Thames	14	17		31	9	3	33		36	8	2	22	8	32	7
North West Coast	63	4	9	76	3	14	15		29	7	10	12	7	29	5
North West London	1			1	15		2		2	14		6		6	10
South London	43	2		45	5	56	18		74	2	28	55	1	84	1
South West Peninsula	19	1	3	23	8	5	1		6	10	5	3		8	9
Thames Valley and South Midlands	30	14		44	4	21	27		48	5	8	9		17	6
Wessex	7	3	26	36	6	5	1	1	7	11	7		4	11	8
West Midlands	14	2	13	29	11	8	6		14	12		8		8	11
West of England	27		2	29	7	24	19		43	6					14 - 15
Yorkshire and Humber	34	7	212	253	1	13	53	102	168	1	17	25	65	107	2

Skin Cancer - Trust Recruitment Overview



Skin Cancer - Large Acute Trusts

Trust Name	2014/15		2015/16		2016/17	
	Recruitment	Rank	Recruitment	Rank	Recruitment	Rank
CALDERDALE AND HUDDERSFIELD NHS FOUNDATION TRUST	1	15 - 16				
EAST AND NORTH HERTFORDSHIRE NHS TRUST	19	2	16	4	7	2 - 3
GLOUCESTERSHIRE HOSPITALS NHS FOUNDATION TRUST	5	8 - 9				
HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST	13	4	18	3	7	2 - 3
NORFOLK AND NORWICH UNIVERSITY HOSPITALS NHS FOUNDATION TRUST	15	3	52	1	20	1
NORTH BRISTOL NHS TRUST			19	2		
PENNINE ACUTE HOSPITALS NHS TRUST	3	12	3	6		
PLYMOUTH HOSPITALS NHS TRUST	4	10 - 11				
ROYAL CORNWALL HOSPITALS NHS TRUST	11	5	5	5	5	4 - 5
ROYAL DEVON AND EXETER NHS FOUNDATION TRUST	2	13 - 14			3	7
SOUTH TEES HOSPITALS NHS FOUNDATION TRUST	1	15 - 16			4	6
THE ROYAL WOLVERHAMPTON NHS TRUST	2	13 - 14				
UNITED LINCOLNSHIRE HOSPITALS NHS TRUST	10	6 - 7				
UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST	4	10 - 11				
UNIVERSITY HOSPITALS OF NORTH MIDLANDS NHS TRUST	10	6 - 7				
WORCESTERSHIRE ACUTE HOSPITALS NHS TRUST	5	8 - 9				
LANCASHIRE TEACHING HOSPITALS NHS FOUNDATION TRUST	30	1	2	7	5	4 - 5

Skin Cancer - Medium Acute Trusts



National Institute for
Health Research

Trust Name	2014/15		2015/16		2016/17	
	Recruitment	Rank	Recruitment	Rank	Recruitment	Rank
AINTREE UNIVERSITY HOSPITAL NHS FOUNDATION TRUST					4	3
IPSWICH HOSPITAL NHS TRUST					1	5 - 6
MID ESSEX HOSPITAL SERVICES NHS TRUST	9	3	22	1	13	1
POOLE HOSPITAL NHS FOUNDATION TRUST	10	2				
SOUTHEND UNIVERSITY HOSPITAL NHS FOUNDATION TRUST	3	4 - 5	1	5		
TAUNTON AND SOMERSET NHS FOUNDATION TRUST	3	4 - 5				
THE ROYAL BOURNEMOUTH AND CHRISTCHURCH HOSPITALS NHS FOUNDATION TRUST					1	5 - 6
ROYAL SURREY COUNTY HOSPITAL NHS FOUNDATION TRUST	2	6	3	4		
ST HELENS AND KNOWSLEY HOSPITAL SERVICES NHS TRUST	15	1	14	2	7	2
THE ROTHERHAM NHS FOUNDATION TRUST	1	7				
YORK TEACHING HOSPITAL NHS FOUNDATION TRUST			5	3	3	4

Skin Cancer - Small Acute Trusts

Trust Name	2014/15		2015/16		2016/17	
	Recruitment	Rank	Recruitment	Rank	Recruitment	Rank
BURTON HOSPITALS NHS FOUNDATION TRUST	2	3 - 4				
SALISBURY NHS FOUNDATION TRUST	2	3 - 4				
SOUTH WARWICKSHIRE NHS FOUNDATION TRUST	1	5 - 6				
YEOVIL DISTRICT HOSPITAL NHS FOUNDATION TRUST	3	2	1	1		
KETTERING GENERAL HOSPITAL NHS FOUNDATION TRUST	5	1				
DORSET COUNTY HOSPITAL NHS FOUNDATION TRUST	1	5 - 6				

Skin Cancer - Open Studies



National Institute for
Health Research

Study ID	Study Short Name	Commercial Study	ROYAL CORNWALL HOSPITALS NHS TRUST	ROYAL DEVON AND EXETER NHS FOUNDATION TRUST
19090	SelPac	Non-Commercial		3
20346	CANC - 5280	Commercial	5	

Skin Cancer – Commercial EOIs 2016-17



National Institute for
Health Research

Type	Study Title	Site Name	Investigator Name	Date Received	Date Sent Out	Service Deadline	Date Returned	Response (negative code, or positive)
Site ID	CANC 31224 An Exploratory Tumor Biopsy-driven Study to Understand the Relationship between Baseline and Post-treatment Tumor and Immune-related Biomarkers and Indicators of Clinical Response in Immunomodulatory Treatment-naïve Unresectable Stage III/IV Melanoma Patients Receiving REGN2810 (Anti-PD-1)	PHNT		12/07/2016	12/07/2016	28/07/2016	27/07/2016	4 - Lack of Eligible Patients
Site ID	CANC 31224 An Exploratory Tumor Biopsy-driven Study to Understand the Relationship between Baseline and Post-treatment Tumor and Immune-related Biomarkers and Indicators of Clinical Response in Immunomodulatory Treatment-naïve Unresectable Stage III/IV Melanoma Patients Receiving REGN2810 (Anti-PD-1)	RD&E		12/07/2016	12/07/2016	28/07/2016		
Site ID	CANC 31224 An Exploratory Tumor Biopsy-driven Study to Understand the Relationship between Baseline and Post-treatment Tumor and Immune-related Biomarkers and Indicators of Clinical Response in Immunomodulatory Treatment-naïve Unresectable Stage III/IV Melanoma Patients Receiving REGN2810 (Anti-PD-1)	RCHT		12/07/2016	12/07/2016	28/07/2016	05/08/2016	8 - No PI Response
Site Intel	CANC 32773 TRILOGY; A PHASE III, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF FATEZOLIZUMAB PLUS COBIMETINIB AND VEMURAFENIB VERSUS PLACEBO PLUS COBIMETINIB AND VEMURAFENIB IN PREVIOUSLY UNTREATED BRAFV600MUTATION-POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA	RCHT	Dr Toby Talbot	01/11/2016	02/11/2016	18/11/2016	04/11/2016	Positive

Skin Cancer – Non Commercial EOIs

2016-17



National Institute for
Health Research

Study Title	Trust Name	Date Sent Out	Deadline	Response	Response Date
SELPAC	RCHT	29/03/2016	15/04/2016	No Reply	27/04/2016